Therapy-related myeloid neoplasms following treatment with radioiodine

Haematologica

Volumn 97, Issue 2, 2012, Pages 206-212

  Schroeder, Thomas ^a   Kuendgen, Andrea ^a   Kayser, Sabine ^b   Kröger, Nicolaus ^c   Braulke, Friederike ^d   Platzbecker, Uwe ^e   Klärner, Viola ^a   Zohren, Fabian ^a   Haase, Detlef ^d   Stadler, Michael ^f   Schlenk, Richard ^b   Czibere, Akos G ^a   Bruns, Ingmar ^a   Fenk, Roland ^a   Gattermann, Norbert ^a   Haas, Rainer ^a   Kobbe, Guido ^a   Germing, Ulrich ^a  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b UNIVERSITY HOSPITAL ULM   (Germany)

^c UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

^f HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

Acute myeloid leukemia; Myelodysplastic syndromes; Radioiodine; Secondary; Therapy related; Thyroid

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; ANTHRACYCLINE; AZACITIDINE; CYCLOSPORIN A; CYTARABINE; HYDROXYUREA; PROTEIN FARNESYLTRANSFERASE INHIBITOR; RADIOACTIVE IODINE; RETINOIC ACID; THYMOCYTE ANTIBODY; VALPROIC ACID;

ACUTE GRANULOCYTIC LEUKEMIA; ADULT; AGED; ARTICLE; BLOOD TRANSFUSION; BONE MARROW TUMOR; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CARCINOID; CHROMOSOME 7; CHRONIC MYELOMONOCYTIC LEUKEMIA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOGENETICS; FEMALE; GENE MUTATION; GRAFT VERSUS HOST REACTION; GRAVES DISEASE; HEMATOLOGICAL PARAMETERS; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; IRON CHELATION; KARYOTYPE; LATENT PERIOD; LEUKOCYTE COUNT; LOW DRUG DOSE; MALE; MYELODYSPLASTIC SYNDROME; OVERALL SURVIVAL; PROGNOSIS; REFRACTORY ANEMIA WITH EXCESS BLASTS; REFRACTORY ANEMIA WITH RINGED SIDEROBLASTS; REFRACTORY CYTOPENIA WITH MULTILINEAGE DYSPLASIA; RETROSPECTIVE STUDY; RISK ASSESSMENT; SCORING SYSTEM; THROMBOTIC THROMBOCYTOPENIC PURPURA; THYROID CANCER; THYROID DISEASE; TREATMENT RESPONSE;

ADULT; AGED; AGED, 80 AND OVER; FEMALE; HUMANS; IODINE RADIOISOTOPES; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; MYELODYSPLASTIC SYNDROMES; NEOPLASMS, RADIATION-INDUCED; NEOPLASMS, SECOND PRIMARY; RETROSPECTIVE STUDIES; SURVIVAL RATE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84856450879     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049114     Document Type: Article

References (31)

1. Vardiman JW, Thiele J, Arber DA, Brunning RD, Borowitz MJ, Porwit A, et al. The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. Blood. 2009;114(5):937-51.
2. Sill H, Olipitz W, Zebisch A, Schulz E, Wölfler A. Therapy-related myeloid neoplasms: pathobiology and clinical characteristics. Br J Pharmacol. 2011;162(4):792-805.
3. Leone G, Pagano L, Ben-Yehuda D, Voso MT. Therapy-related leukemia and myelodysplasia: susceptibility and incidence. Haematologica. 2007;92(10):1389-98.
4. Germing U, Aul C, Niemeyer CM, Haas R, Bennett JM. Epidemiology, classification and prognosis of adults and children with myelodysplastic syndromes. Ann Hematol. 2008;87(9):691-9.
5. Knipp S, Hildebrandt B, Richter J, Haas R, Germing U, Gattermann N. Secondary myelodysplastic syndromes following treatment with azathioprine are associated with aberrations of chromosome 7. Haemato -logica. 2005;90(5):691-3.
6. Offman J, Opelz G, Doehler B, Cummins D, Halil O, Banner NR, et al. Defective DNA mismatch repair in acute myeloid leukemia/myelodysplastic syndrome after organ transplantation. Blood. 2004;104(3): 822-8.
7. Kayser S, Döhner K, Krauter J, Köhne CH, Horst HA, Held G, et al. The impact of therapy-related acute myeloid leukemia (AML) on outcome in 2853 adult patients with newly diagnosed AML. Blood. 2011;117(7): 2137-45.
8. Godley LA, Larson RA. Therapy-related myeloid leukemia. Semin Oncol. 2008; 35(4):418-29.
9. Smith SM, Le Beau MM, Huo D, Karrison T, Sobecks RM, Anastasi J, et al. Clinical-cyto-genetic associations in 306 patients with therapy-related myelodysplasia and myeloid leukemia: the University of Chicago series. Blood. 2003;102(1):43-52.
10. Schoch C, Kern W, Schnittger S, Hiddemann W, Haferlach T. Karyotype is an independent prognostic parameter in therapy-related acute myeloid leukemia (t-AML): an analysis of 93 patients with t-AML in comparison to 1091 patients with de novo AML. Leukemia. 2004;18(1):120-5.
11. Kuendgen A, Mende C, Haase D, Fischer F, Hildebrandt B, Giagounidis A, et al. Prognostic factors in treatment-related myelodysplastic syndromes (t-MDS) and acute myeloid leukemia (t-AML). Blood (ASH Annual Meeting Abstracts); 110: 2451.
12. Iwanaga M, Hsu WL, Soda M, Takasaki Y, Tawara M, Joh T, et al. Risk of myelodys-plastic syndromes in people exposed to ionizing radiation: a retrospective cohort study of Nagasaki atomic bomb survivors. J Clin Oncol. 2011;29(4):428-34.
13. Abraham P, Acharya S. Current and emerging treatment options for Graves' hyperthy-roidism. Ther Clin Risk Manag. 2010;6:29-40.
14. Brown RL. Standard and emerging therapeutic approaches for thyroid malignancies. Semin Oncol. 2008;35(3):298-308.
15. Focosi D, Galimberti S, Petrini M. Acute myeloid leukemia and follicular lymphoma after very low dose radioiodine therapy for thyroid diseases. Haematologica. 2007;92 (9):e96-7.
16. Grudeva-Popova J, Yaneva M, Zisov K, Ananoshtev N. Therapy-related acute promyelocytic leukemia after treatment with radioiodine for thyroid cancer: case report with literature review. J BUON. 2007;12(1):129-32.
17. Döhner H, Estey EH, Amadori S, Appelbaum FR, Büchner T, Burnett AK, et al. Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood. 2010;115(3):453-74.
18. Hoffman DA, McConahey WM, Fraumeni JF Jr, Kurland LT. Cancer incidence following treatment of hyperthyroidism. Int J Epidemiol. 1982;11(3):218-24.
19. Hall P, Holm LE. Late consequences of radioiodine for diagnosis and therapy in Sweden. Thyroid. 1997;7(2):205-8.
20. de Vathaire F. The carcinogenic effects of radioiodine therapy for thyroid carcinoma. Nat Clin Pract Endocrinol Metab. 2008;4 (4):180-1.
21. Edmonds CJ, Smith T. The long-term hazards of the treatment of thyroid cancer with radioiodine. Br J Radiol. 1986;59(697): 45-51.
22. Sawka AM, Thabane L, Parlea L, Ibrahim-Zada I, Tsang RW, Brierley JD, et al. Second primary malignancy risk after radioactive iodine treatment for thyroid cancer: a systematic review and meta-analysis. Thyroid. 2009;19(5):451-7.
23. Breems DA, Van Putten WL, De Greef GE, Van Zelderen-Bhola SL, Gerssen-Schoorl KB, Mellink CH, et al. Monosomal kary-otype in acute myeloid leukemia: a better indicator of poor prognosis than a complex karyotype. J Clin Oncol. 2008;26(29):4791-7.
24. Haase D, Germing U, Schanz J, Pfeilstöcker M, Nösslinger T, Hildebrandt B, et al. New insights into the prognostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood. 2007;110(13):4385-95.
25. Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, et al. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. Chem Biol Interact. 2010;184(1-2):50-7.
26. Bacher U, Haferlach T, Kern W, Haferlach C, Schnittger S. A comparative study of molecular mutations in 381 patients with myelodysplastic syndrome and in 4130 patients with acute myeloid leukemia. Haematologica. 2007;92(6):744-52.
27. Christiansen DH, Andersen MK, Desta F, Pedersen-Bjergaard J. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia. Leukemia. 2005;19(12): 2232-40.
28. Chen CY, Lin LI, Tang JL, Ko BS, Tsay W, Chou WC, et al. RUNX1 gene mutation in primary myelodysplastic syndrome--the mutation can be detected early at diagnosis or acquired during disease progression and is associated with poor outcome. Br J Haematol. 2007;139(3):405-14.
29. Gaidzik VI, Bullinger L, Schlenk RF, Zimmermann AS, Röck J, Paschka P, et al. RUNX1 mutations in acute myeloid leukemia: results from a comprehensive genetic and clinical analysis from the AML Study Group. J Clin Oncol. 2011;29(10): 1364-72.
30. Kröger N, Brand R, van Biezen A, Zander A, Dierlamm J, Niederwieser D, et al. Risk factors for therapy-related myelodysplastic syndrome and acute myeloid leukemia treated with allogeneic stem cell transplantation. Haematologica. 2009;94(4):542-9.
31. Kantarjian HM, Estey EH, Keating MJ. Treatment of therapy-related leukemia and myelodysplastic syndrome. Hematol Oncol Clin North Am. 1993;7(1):81-107.